211 related articles for article (PubMed ID: 37406115)
1. Melanoma-intrinsic NR2F6 activity regulates antitumor immunity.
Kim H; Feng Y; Murad R; Pozniak J; Pelz C; Chen Y; Dalal B; Sears R; Sergienko E; Jackson M; Ruppin E; Herlyn M; Harris C; Marine JC; Klepsch V; Baier G; Ronai ZA
Sci Adv; 2023 Jul; 9(27):eadf6621. PubMed ID: 37406115
[TBL] [Abstract][Full Text] [Related]
2. Loss of the orphan nuclear receptor NR2F6 enhances CD8
Jakic B; Olson WJ; Siegmund K; Klepsch V; Kimpel J; Labi V; Zehn D; Baier G; Hermann-Kleiter N
Cell Death Dis; 2021 Feb; 12(2):187. PubMed ID: 33589606
[TBL] [Abstract][Full Text] [Related]
3. Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy.
Klepsch V; Hermann-Kleiter N; Baier G
Immunol Lett; 2016 Oct; 178():31-6. PubMed ID: 26992368
[TBL] [Abstract][Full Text] [Related]
4. The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance.
Hermann-Kleiter N; Klepsch V; Wallner S; Siegmund K; Klepsch S; Tuzlak S; Villunger A; Kaminski S; Pfeifhofer-Obermair C; Gruber T; Wolf D; Baier G
Cell Rep; 2015 Sep; 12(12):2072-85. PubMed ID: 26387951
[TBL] [Abstract][Full Text] [Related]
5. Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy.
Klepsch V; Pommermayr M; Humer D; Brigo N; Hermann-Kleiter N; Baier G
Cell Commun Signal; 2020 Jan; 18(1):8. PubMed ID: 31937317
[TBL] [Abstract][Full Text] [Related]
6. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
7. Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6.
Klepsch V; Siegmund K; Baier G
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073258
[TBL] [Abstract][Full Text] [Related]
8. Orphan Nuclear Receptor NR2F6 Suppresses T Follicular Helper Cell Accumulation through Regulation of IL-21.
Olson WJ; Jakic B; Labi V; Schoeler K; Kind M; Klepsch V; Baier G; Hermann-Kleiter N
Cell Rep; 2019 Sep; 28(11):2878-2891.e5. PubMed ID: 31509749
[TBL] [Abstract][Full Text] [Related]
9. Induction of Progenitor Exhausted Tissue-Resident Memory CD8
León-Letelier RA; Castro-Medina DI; Badillo-Godinez O; Tepale-Segura A; Huanosta-Murillo E; Aguilar-Flores C; De León-Rodríguez SG; Mantilla A; Fuentes-Pananá EM; López-Macías C; Bonifaz LC
Front Immunol; 2020; 11():583382. PubMed ID: 33240271
[TBL] [Abstract][Full Text] [Related]
10. Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.
Klepsch V; Hermann-Kleiter N; Do-Dinh P; Jakic B; Offermann A; Efremova M; Sopper S; Rieder D; Krogsdam A; Gamerith G; Perner S; Tzankov A; Trajanoski Z; Wolf D; Baier G
Nat Commun; 2018 Apr; 9(1):1538. PubMed ID: 29670099
[TBL] [Abstract][Full Text] [Related]
11. High throughput screening for compounds to the orphan nuclear receptor NR2F6.
Smith E; Campbell S; Wilson AN; Shumate J; Baillargeon P; Scampavia L; Kamenecka TM; Spicer TP; Solt LA
SLAS Discov; 2022 Jun; 27(4):242-248. PubMed ID: 35331960
[TBL] [Abstract][Full Text] [Related]
12. [The role of nuclear receptor transcription factor NR2F6 in tumor].
Huang L; Liu J; Zhu Y; Zhou Q; Xiao B; Sun Z; Li L
Sheng Wu Gong Cheng Xue Bao; 2021 Aug; 37(8):2595-2602. PubMed ID: 34472280
[TBL] [Abstract][Full Text] [Related]
13. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
14. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade.
Wang M; Huang Y; Chen M; Wang W; Wu F; Zhong T; Chen X; Wang F; Li Y; Yu J; Wu M; Chen D
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37620043
[TBL] [Abstract][Full Text] [Related]
16. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
17. Incomplete thermal ablation-induced up-regulation of transcription factor nuclear receptor subfamily 2, group F, member 6 (NR2F6) contributes to the rapid progression of residual liver tumor in hepatoblastoma.
Pang JS; Wen DY; He RQ; Chen G; Lin P; Li JH; Zhao YJ; Wu LY; Chen JH; He Y; Qin LT; Chen JB; Li Y; Yang H
Bioengineered; 2021 Dec; 12(1):4289-4303. PubMed ID: 34304715
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients.
Proppe L; Jagomast T; Beume S; Klapper L; Gitas G; Köster F; Perner S; Rody A; Ribbat-Idel J; Hanker LC
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7155-7164. PubMed ID: 36884115
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
20. A role for the nuclear receptor NR2F6 in peritoneal B cell homeostasis.
Olson WJ; Jakic B; Labi V; Woelk J; Derudder E; Baier G; Hermann-Kleiter N
Front Immunol; 2022; 13():845235. PubMed ID: 36052079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
